Since increased nuclear STAT1 is associated with a better survival in CRC patients (222) and Th1 polarization – also induced through IFN-γ – correlates with prolonged survival of CRC patients (15), immunomodulatory approaches selectively inducing IFN-γ production may be considered for CRC therapy. The gene discussed is STAT1; the disease is colorectal carcinoma.